January 3, 2012 -- ProteoTech, a privately held Seattle-area biotech company, will collaborate with GSK China to develop a small molecule therapeutic aimed at Parkinson’s disease. Steve Runnels, CEO of ProteoTech, told ChinaBio® Today the agreement was signed with GSK’s China unit because its Shanghai research center has responsibility for development of CNS drugs in GSK’s system. More details....
Stock Symbol: (NYSE: GSK)
